Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine.

After the administration of the first dose, a trend toward a higher incidence of solicited systemic adverse events was noted with the higher vaccine dose, and a clear trend for decreasing grade 3 adverse events with increasing age was observed.

also in 19,460 other papers